27 related articles for article (PubMed ID: 1581905)
1.
Kunakom S; Eustáquio AS
J Nat Prod; 2019 Jul; 82(7):2018-2037. PubMed ID: 31294966
[No Abstract] [Full Text] [Related]
2. Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?
Fanale D; Bronte G; Passiglia F; Calò V; Castiglia M; Di Piazza F; Barraco N; Cangemi A; Catarella MT; Insalaco L; Listì A; Maragliano R; Massihnia D; Perez A; Toia F; Cicero G; Bazan V
Anal Cell Pathol (Amst); 2015; 2015():690916. PubMed ID: 26484003
[TBL] [Abstract][Full Text] [Related]
3. Microtubule-binding agents: a dynamic field of cancer therapeutics.
Dumontet C; Jordan MA
Nat Rev Drug Discov; 2010 Oct; 9(10):790-803. PubMed ID: 20885410
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo modulation by rhizoxin of non-P-glycoprotein-mediated vindesine resistance.
Arioka H; Nishio K; Heike Y; Abe S; Saijo N
J Cancer Res Clin Oncol; 1997; 123(4):195-200. PubMed ID: 9177491
[TBL] [Abstract][Full Text] [Related]
5. Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group.
Kaplan S; Hanauske AR; Pavlidis N; Bruntsch U; te Velde A; Wanders J; Heinrich B; Verweij J
Br J Cancer; 1996 Feb; 73(3):403-5. PubMed ID: 8562351
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of rhizoxin in squamous cell head and neck cancer. The EORTC Early Clinical Trials Group.
Verweij J; Wanders J; Gil T; Schöffski P; Catimel G; te Velde A; de Mulder PH
Br J Cancer; 1996 Feb; 73(3):400-2. PubMed ID: 8562350
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.
Hanauske AR; Catimel G; Aamdal S; ten Bokkel Huinink W; Paridaens R; Pavlidis N; Kaye SB; te Velde A; Wanders J; Verweij J
Br J Cancer; 1996 Feb; 73(3):397-9. PubMed ID: 8562349
[TBL] [Abstract][Full Text] [Related]
8. Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine.
Rowinsky EK; Citardi MJ; Noe DA; Donehower RC
J Cancer Res Clin Oncol; 1993; 119(12):727-33. PubMed ID: 8104946
[TBL] [Abstract][Full Text] [Related]
9. P glycoprotein (P-gp) and drug resistance--time for reappraisal?
Kaye SB
Br J Cancer; 1993 Apr; 67(4):641-3. PubMed ID: 8097103
[No Abstract] [Full Text] [Related]
10. Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer.
Kerr DJ; Rustin GJ; Kaye SB; Selby P; Bleehen NM; Harper P; Brampton MH
Br J Cancer; 1995 Nov; 72(5):1267-9. PubMed ID: 7577480
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors.
Tolcher AW; Aylesworth C; Rizzo J; Izbicka E; Campbell E; Kuhn J; Weiss G; Von Hoff DD; Rowinsky EK
Ann Oncol; 2000 Mar; 11(3):333-8. PubMed ID: 10811501
[TBL] [Abstract][Full Text] [Related]
12. Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.
McLeod HL; Murray LS; Wanders J; Setanoians A; Graham MA; Pavlidis N; Heinrich B; ten Bokkel Huinink WW; Wagener DJ; Aamdal S; Verweij J
Br J Cancer; 1996 Dec; 74(12):1944-8. PubMed ID: 8980394
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and early clinical studies of selected new drugs.
Kaye SB; Workman P; Graham MA; Cassidy J; Jodrell D
Cancer Surv; 1993; 17():371-96. PubMed ID: 8137348
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of rhizoxin.
Bissett D; Graham MA; Setanoians A; Chadwick GA; Wilson P; Koier I; Henrar R; Schwartsmann G; Cassidy J; Kaye SB
Cancer Res; 1992 May; 52(10):2894-8. PubMed ID: 1581905
[TBL] [Abstract][Full Text] [Related]
16. Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme.
Graham MA; Bissett D; Setanoians A; Hamilton T; Kerr DJ; Henrar R; Kaye SB
J Natl Cancer Inst; 1992 Apr; 84(7):494-500. PubMed ID: 1545439
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
